Barbarot, Sebastien, Rogers, Natasha K., Abuabara, Katrina, Aubert, Helene, Chalmers, Joanne, Flohr, Carsten, Hanfin, Jon, Naldi, Luigi, Margolis, David J., Paul, Carle, Ridd, Matthew J., Schuttelaar, Marie-Louise Anna, Simpson, Eric, Tauber, Marie, Volke, Annika, Weidinger, Stephan, Wilkes, Sally R., Wollenberg, Andreas and Thomas, Kim S.
(2016)
Strategies for measuring long-term control in atopic dermatitis trials: a systematic review.
Journal of the American Academy of Dermatology, 75
(5).
pp. 1038-1044.
ISSN 1523-1747
Full text not available from this repository.
Abstract
Background: Atopic dermatitis (AD) is a chronic inflammatory skin disease. There are no standardised methods for capturing long-term control of AD.
Objective: To identify how long-term control has been captured in published randomised controlled trials (RCTs). Resultswill initiate consensus discussions on how best to measure long-term control in the core outcome set for AD.
Methods: Systematic review of RCTs of AD treatments published between 2000 and 2013, with a follow-up period of ≥3 months, at least one outcome measure recorded at ≥3 time-points, full paper available, and published in English.
Results: 101/ 353 RCTs were eligible. Methods to capture long-term control included: repeated measurement of AD outcomes (92 RCTs; 91%), use of AD medication (29 RCTs; 28.7%); and AD flares/remissions (26 RCTs; 25.7%). Repeated measurements of AD outcomes were typically collected 3 to 5 times during a trial, but analysis methods often failed to make best use of the data. Time to first flare was most commonly for trials including flare data (21/52). Medication-use was recorded based on quantity, potency and frequency of application. Limitations: Included RCT data only
Conclusion: This review illustrates the difficulties in measuring long-term control, and points to the need for improved harmonization of outcomes.
Actions (Archive Staff Only)
 |
Edit View |
Tools
Tools
